Inhibikase Therapeutics Inc (IKT) financials
Inhibikase Therapeutics revenue and earnings by year
Inhibikase Therapeutics's revenue was $260,501 in the fiscal year to December 31, 2023, up 111.0% from the year before. Net income was -$19.0 million, -7304.7% of revenue. Since the fiscal year to December 31, 2018, revenue has shrunk 42.2% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 6 fiscal years
| Fiscal year to | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 3 | 1 | 1 | 4 |
| Revenue growth | 111.0% | -96.0% | 343.9% | -37.8% | -72.2% | — |
| Operating income | -20 | -18 | -15 | -3 | -6 | -2 |
| Operating margin | -7712.0% | -14686.2% | -476.2% | -403.5% | -507.5% | -52.5% |
| Net income | -19 | -18 | -15 | -3 | -6 | -2 |
| Net margin | -7304.7% | -14625.9% | -476.9% | -407.7% | -509.7% | -53.3% |
| Diluted EPS | -$3.16 | -$4.28 | — | — | — | — |
| Free cash flow | -18 | -18 | -14 | -1 | -0 | 1 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open IKT in Markets.
See also: IKT returns
No forecast, no recommendation. This page describes Inhibikase Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.